MSU
TLSI icon

Mizuho Securities USA’s TriSalus Life Sciences TLSI Stock Holding History

Mizuho Securities USA’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-457,429
Closed -$4.51M – 213
2022
Q3 		$4.51M Buy
+457,429
New +$4.53M 0.61% 57
2021
Q4 		– Sell
-36,490
Closed -$362K – 213
2021
Q3 		$362K Buy
+36,490
New +$357K 0.04% 208

Other funds holding TLSI

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Mizuho Securities USA's TLSI Position: Q4 2022 in Review

Mizuho Securities USA sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 457,429 shares — an estimated $4.51M sold.

Mizuho Securities USA first reported a position in TLSI in Q3 2021 and held it in 2 quarters. The position peaked at $4.51M in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Mizuho Securities USA reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Mizuho Securities USA sold 457,429 TriSalus Life Sciences shares in Q4 2022, an estimated $4.51M.
  • Mizuho Securities USA first reported a position in TriSalus Life Sciences in Q3 2021 and held it in 2 quarters.
  • Mizuho Securities USA's TriSalus Life Sciences position peaked at $4.51M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Mizuho Securities USA's 13F filing for Q4 2022, filed 3 Feb 2023.